Adipose derived mesenchymal stem cell secretome formulation as a biotherapeutic to inhibit growth of drug resistant triple negative breast cancer

In the present study, a protocol was developed for processing of human adipose derived mesenchymal stem cell secretome formulation of varying concentration. Its molecular composition was evaluated, and its effectiveness in vitro using breast cancer cell lines, and in vivo in a nude mice breast cancer model was studied to determine its role in suppressing triple negative breast cancer in a dose dependent manner. Because the secretome could have value as an add-on therapy along with a current drug, the effectiveness of the secretome both in monotherapy and in combination therapy along with paclitaxel was evaluated. The results showed significant cell kill when exposed to the secretome above 20 mg/ml at which concentration there was no toxicity to normal cells. 70 mg/ml of SF showed 90 +/- 10% apoptosis and significant decrease in CD44(+)/CD24(-), MDR1+ and PDL-1+ cancer cells. In vivo, the tumor showed no growth after daily intra tumor injections at 50 mg/ml and 100 mg/ml doses whereas substantial tumor growth occurred after saline intra tumor injection. The study concludes that SF is a potential biotherapeutic for breast cancer and could be used initially as an add-on therapy to other standard of care to provide improved efficacy without other adverse effects.

Automated summary

The study developed a protocol for processing human adipose-derived mesenchymal stem cell secretome of varying concentrations and evaluated its molecular composition and effectiveness in vitro and in vivo for suppressing triple negative breast cancer in a dose-dependent manner. The secretome demonstrated significant cell kill above 20 mg/ml without toxicity to normal cells, and showed potential as a biotherapeutic for breast cancer when administered in daily intra-tumor injections at 50 mg/ml and 100 mg/ml doses.